Body Composition and Adipose Tissue in HIV

checkorphan
Learn more about:
Lipodystrophy
Related Clinical Trial
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptraâ„¢ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Body Composition and Adipose Tissue in HIV

Official Title

Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy

Brief Summary

      In this study, the investigators will examine the effect of therapy with the Growth Hormone
      Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV
      lipodystrophy and central adiposity. This study is a single arm prospective study of
      tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition
      testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity
      assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous
      injection.

Detailed Description

      HIV lipodystrophy is increasingly recognized as a common and clinically significant long-term
      sequelae of HIV treatment. In the HIV lipodystrophy lipohypertrophy phenotype, visceral
      adipose tissue (VAT) is increased and this is associated with reduced growth hormone (GH)
      secretion. Mounting evidence also links this phenotype with dyslipidemia, insulin resistance,
      subclinical atherosclerosis and cardiovascular (CV) disease in patients with HIV disease. The
      etiology of HIV lipodystrophy (HIVLD) with central adiposity is unclear, but this phenotype
      is increasingly common with newer, less lipotoxic combination anti-retroviral therapy (cART)
      use. VAT and hepatic lipid accumulation, are important health concerns for HIVLD patients.
      This body composition pattern may contribute to the increased cardiovascular risk that has
      been demonstrated in patients with HIV lipodystrophy. Patients with HIVLD and central
      adiposity have been shown to have reduced GH secretion. Thus, a medication has been developed
      to augment GH secretion. This medication is tesamorelin. GH supplementation in other clinical
      settings has been shown to reduce visceral adiposity and may reduce hepatic lipid content.

Study Phase

Phase 4

Study Type

Interventional

Primary Outcome

Change in Hepatic Lipid Content

Secondary Outcome

 Change in Visceral Adipose Tissue (VAT) mass

Condition

HIV Lipodystrophy Syndrome

Intervention

Tesamorelin

Study Arms / Comparison Groups

 Tesamorelin
Description:  Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

24

Start Date

February 7, 2018

Completion Date

April 30, 2022

Primary Completion Date

April 30, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  HIV-infected subjects with HIV lipodystrophy (HIVLD)

          -  Abdominal fat accumulation defined as: Waist Circumference (WC) 102 cm for men, 88 cm
             for women, except in subjects of East/South Asian ethnicity in whom this will be
             defined by WC 90 cm for men and 80 cm for women.

          -  Weight stable for 8 weeks prior to enrollment,

          -  CD4 count >100 cells/mm3

          -  HIV RNA load <1000 copies/mL

          -  Fasting plasma glucose <120 mg/dL

          -  Stable combination anti-retroviral therapy (cART) of any regimen for ≥ 8 weeks prior
             to study enrollment

        Exclusion Criteria:

          -  Diabetes mellitus requiring medication

          -  History of any malignancy

          -  Abnormal renal or liver function

          -  Pregnancy or women of childbearing age who are not using an acceptable means of
             contraception

          -  History disorder of the hypothalamic-pituitary axis due to hypophysectomy,
             hypopituitarism or pituitary tumor/surgery

          -  Head irradiation or head trauma or adrenal insufficiency

          -  Systemic glucocorticoid use

          -  Known hypersensitivity to tesamorelin and/or mannitol

Gender

All

Ages

18 Years - 68 Years

Accepts Healthy Volunteers

No

Contacts

Pamela U. Freda, MD, 212-305-4921, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT03226821

Organization ID

AAAR2634

Secondary IDs

R01DK110771

Responsible Party

Principal Investigator

Study Sponsor

Columbia University

Collaborators

 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Sponsor

Pamela U. Freda, MD, Principal Investigator, Columbia University

Verification Date

July 2021